OPDIVO SQVANTIG Trademark

Trademark Overview

On Wednesday, November 23, 2022, a trademark application was filed for OPDIVO SQVANTIG with the United States Patent and Trademark Office. The USPTO has given the OPDIVO SQVANTIG trademark a serial number of 97690352. The federal status of this trademark filing is SECOND EXTENSION - GRANTED as of Tuesday, August 20, 2024. This trademark is owned by Bristol-Myers Squibb Company. The OPDIVO SQVANTIG trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations for human use for the treatment and prevention of cancer
opdivo sqvantig

General Information

Serial Number97690352
Word MarkOPDIVO SQVANTIG
Filing DateWednesday, November 23, 2022
Status731 - SECOND EXTENSION - GRANTED
Status DateTuesday, August 20, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, July 11, 2023

Trademark Statements

Goods and ServicesPharmaceutical preparations for human use for the treatment and prevention of cancer

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateMonday, November 28, 2022
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameBristol-Myers Squibb Company
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressPrinceton, NJ 08543
Party NameBristol-Myers Squibb Company
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressNew York, NY 10016

Trademark Events

Event DateEvent Description
Monday, November 28, 2022NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Saturday, November 26, 2022NEW APPLICATION ENTERED
Sunday, February 26, 2023ASSIGNED TO EXAMINER
Wednesday, March 8, 2023NON-FINAL ACTION WRITTEN
Wednesday, March 8, 2023NON-FINAL ACTION E-MAILED
Wednesday, March 8, 2023NOTIFICATION OF NON-FINAL ACTION E-MAILED
Friday, June 2, 2023TEAS RESPONSE TO OFFICE ACTION RECEIVED
Friday, June 2, 2023CORRESPONDENCE RECEIVED IN LAW OFFICE
Friday, June 2, 2023TEAS/EMAIL CORRESPONDENCE ENTERED
Saturday, June 3, 2023APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, June 21, 2023NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, July 11, 2023PUBLISHED FOR OPPOSITION
Tuesday, July 11, 2023OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Wednesday, August 2, 2023TEAS CHANGE OF OWNER ADDRESS RECEIVED
Wednesday, August 2, 2023APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Wednesday, August 2, 2023TEAS CHANGE OF CORRESPONDENCE RECEIVED
Tuesday, September 5, 2023NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Wednesday, February 7, 2024SOU EXTENSION 1 FILED
Wednesday, February 7, 2024SOU TEAS EXTENSION RECEIVED
Wednesday, February 7, 2024SOU EXTENSION 1 GRANTED
Tuesday, August 20, 2024SOU TEAS EXTENSION RECEIVED
Tuesday, August 20, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, August 20, 2024SOU EXTENSION 2 GRANTED
Tuesday, August 20, 2024SOU EXTENSION 2 FILED
Friday, February 9, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED

Related Keywords

sqvantig opdivo prevention cancer treatment human preparations pharmaceutical